— Yield laundry
— Gross profit (excluding the depreciation expense of the purchase price allocation) was
Key Operational Statistics:
— Even under the impact of Covid-19, revenues from the Transcatheter Valve Therapeutic Business and Neurointerventional Business were
— For the Transcatheter Valve Therapeutic Business, both product adoption by new hospitals and product usage rates in adopted hospitals exceeded expectations. From
— The Group’s registration applications for four ischemic products have been approved by the NMPA and the product portfolio for the ischemic product line has been provisionally established. The Group can provide a complete set of solutions for hemorrhagic and ischemic stokes. In the first half of 2022, the Group further expanded its share of the sizeable hemorrhagic market and continuously consolidated its leading position in the neuro-interventional industry.
— The Group made continuous efforts to optimize the supply chain and production process to achieve long-term success, and maintained stable production to meet the rapid growth in sales demand in the first half of the year.
During the period, the Group posted a turnover of
The impact of Covid-19 in the first half of 2021 has further validated the Group’s execution capability and operational efficiency. Both business lines exceeded their respective commercialization targets. The Group’s pipeline projects ran smoothly and production activities and the supply chain were well managed. The production fulfillment rate of core products reached approximately 60% (50% as a baseline) in the first half of the year.
Transcatheter Valve Therapeutic business: The commercialization platform was provisionally established, establishing a strong foundation for commercialization success. Products in the pipeline also ran smoothly, making long-term business development more sustainable.
For the Transcatheter Valve Therapeutic Business, the Group had five registered products and nine product candidates in various stages of development. Sales of TaurusOne(R) and TaurusElite(R) products went well. Transcatheter Valve Therapeutic Business revenue grew 455.4% compared to the same period in 2021, despite the impact of the pandemic. From
Excellent product performance and professional market education and promotion have accelerated both product adoption by new hospitals and the utilization rate of our products in the adopted hospitals for our Transcatheter Valve Therapeutic Business. From
The Transcatheter Valve Therapeutic Business has progressed rapidly since its commercial launch, thanks to its cross-functional teams comprised of marketing, sales and medical professionals. The all-round support ranges from academic promotion to collaboration on new technology, from patient identification to physician training, and from pre-operative, intra-operative and post-operative clinical support to meticulous sales service. The rapid development of commercialization has provided a solid cash base for the company’s long-term development.
The Group has developed a competitive product pipeline through external acquisitions and internal development, with a wide range of innovative products under development for key next-generation valve diseases and technologies. From
Among them, three projects are entering major clinical trial phases: GeminiOne(R) and MonarQ will enter the registration clinical trial phase and the foreign FIM clinical trial phases respectively, and HighLife(R) will enter the registration clinical trial phase.
Neurointerventional Business: With the successive launch of four ischemic products by the Group, the product portfolio for the ischemic product line has been provisionally established. The Group can provide a complete set of solutions for hemorrhagic and ischemic strokes. With the increasing sales of hemorrhagic products and the upcoming commercialization of recently approved ischemic products, the revenue composition of the Neurointerventional Business will further diversify.
In the first half of 2022, registration applications of four products have been approved by the NMPA, namely Syphonet(R) Stent Retriever, Tethys AS(R) Aspiration Catheter, Fastunnel(R) Delivery Balloon Dilation Catheter and Fluxcap(R) Balloon Guide Catheter. The product portfolio for the ischemic product line has been tentatively established, with all major devices immediately in place, providing a complete solution for patients with AIS and ICAD.
As of now, the Neurointerventional Business Group had fourteen registered products and seven product candidates in various stages of development. The Group has an extensive portfolio of registered and pipeline products targeting both hemorrhagic and ischemic stroke markets, providing a total solution for both hemorrhagic and ischemic strokes with a complete line of core products. This will not only increase its resilience in times of change and uncertainty, but also increase the attractiveness and synergy of its product portfolio among physicians and distributors.
Thanks to its superior product performance, strong marketing capability and stable and deep distribution network, the Neurointerventional Business revenue increased 57.6% over the period compared to the same period in 2021. Revenue generated from the sale of hemorrhagic, ischemic and vascular access products accounted for 44.2%, 25.0% and 30.6% of total Neurointerventional Business revenue, respectively. With the increasing sales of hemorrhagic products and the upcoming commercialization of recently approved ischemic products, the revenue composition of the Neurointerventional Business will further diversify.
Copyright 2022 ACN Newswire. All rights reserved.
© Japan Corporate News, source